Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1). The molecule is significantly involved in the tight junction between cells. Now the company closed a three digit million Seriec C round.
Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialise antibody therapies.
BioNTech has entered the ADC field with an exclusive license and collaboration agreement with Chinas DualityBio Ltd for two antibody-drug conjugate (ADC) assets.
Pfizer strengthens its oncology portfolio by acquiring Seagen, the biotech specialist in antibody-drug conjugates technology.
Rational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.
SOTIO Biotech a.s. has exercised its first of five exclusive, target-specific options for antibody-drug conjugate (ADC) SOT106 under its agreement with LegoChem Biosciences Inc.
Mablink Bioscience has baged €31m in a Series A round led by Sofinnova Partners and Mérieux Equity Partners to speed up its pipeline of ADCs.
Swiss ADC maker Araris Biotech AG has added a $24m financing round to its CHF15.2m (S17.8m) seed round in 2020 to expand its portfolio of proprietary antibody drug conjugates.
In a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US.